ReviewMetabolic brain disease2026
Ellagic acid can improve stroke by regulating gut microbiota.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is a condition characterized by high rates of morbidity, mortality, and disability. Developing new and effective treatments is critical for improving stroke rehabilitation outcomes. Microbiota-gut-brain axis has garnered significant attention as a bidirectional communication network linking gut microbiota with their host organisms. A considerable number of post-stroke patients develop gastrointestinal complications. The microbiota plays a critical role in both the development and prognosis of stroke. Ellagic acid, which possesses anti-inflammatory and antioxidant properties, may modulate the gut microbiota and thereby improve stroke outcomes. This review focuses on the intricate interplay among gut microbiota, ellagic acid, and stroke pathogenesis and recovery. We systematically analyzed the in vivo metabolism of ellagic acid, elucidating its key biological activities and therapeutic potentials. Concurrently, we pointed out its limitations such as solubility-limited bioavailability. This report highlights that ellagic acid can ameliorate stroke outcomes by modulating gut microbiota, proposes the development of advanced drug delivery systems and bioactive derivatives as promising strategies to enhance its efficacy and translational potential.
Indexed as
Identifiers
41843259What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.